Loading...
ROCO
6242
Market cap26mUSD
Jul 09, Last price  
36.10TWD
1D
0.28%
1Q
-3.86%
Jan 2017
-5.50%
IPO
142.61%
Name

Li Kang Biomedical Co Ltd

Chart & Performance

D1W1MN
ROCO:6242 chart
P/E
10.04
P/S
1.43
EPS
3.60
Div Yield, %
5.54%
Shrs. gr., 5y
2.61%
Rev. gr., 5y
5.23%
Revenues
589m
+4.19%
886,650,000715,655,000505,555,000334,733,000228,712,000168,084,000246,871,000237,349,000255,926,000455,809,000450,608,000495,942,000495,567,000483,297,000456,720,000386,969,000684,253,000629,379,000565,515,000589,209,000
Net income
84m
+8.83%
-5,413,000-152,228,000-117,709,000-67,643,000-103,657,000-47,329,000-35,500,000-61,897,000-26,190,00052,852,00061,510,000133,737,00076,738,00072,016,00069,268,00051,437,000112,094,000110,993,00077,024,00083,824,000
CFO
88m
+35.27%
92,558,00081,666,00060,446,000157,243,00096,744,00065,382,00088,442,000
Dividend
Jun 16, 20252 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Li Kang Biomedical Co., Ltd. specializes in the development and distribution of nutritional supplements, cosmeceuticals, and health-focused beverages. Beyond its product lines, the company also provides consulting and operational support for tourism factories, and offers telemarketing solutions. Established in 1982, the firm initially operated under the name BAFO Technologies Corporation, before adopting its current moniker, Li Kang Biomedical Co., Ltd., in September 2014. The company maintains its headquarters in Tainan City, Taiwan.
IPO date
Jun 18, 2002
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT